7,152 Shares of DaVita Inc. $DVA Purchased by Westwind Capital

Westwind Capital acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the third quarter, Holdings Channel reports. The fund acquired 7,152 shares of the company’s stock, valued at approximately $1,251,000.

Several other institutional investors have also made changes to their positions in the company. Value Investment Professionals LLC raised its holdings in shares of DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after acquiring an additional 50 shares during the period. Kesler Norman & Wride LLC grew its position in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in DaVita by 4.1% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after purchasing an additional 76 shares during the period. CoreCap Advisors LLC boosted its position in shares of DaVita by 161.7% in the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after buying an additional 97 shares during the period. Finally, Root Financial Partners LLC grew its holdings in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 0.2%

Shares of DVA traded down $0.34 during mid-day trading on Thursday, hitting $176.44. 582,204 shares of the company’s stock were exchanged, compared to its average volume of 901,968. The stock has a market cap of $11.26 billion, a price-to-earnings ratio of 14.44, a P/E/G ratio of 0.47 and a beta of 0.80. The firm has a fifty day moving average of $184.82 and a two-hundred day moving average of $189.41. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the prior year, the company posted $2.95 earnings per share. DaVita’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of research reports. Oppenheimer set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Barclays raised their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Weiss Ratings lowered shares of DaVita from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Truist Financial dropped their price target on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $233.43.

DaVita Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.